Milnacipran plasma levels and antidepressant response in Japanese major depressive patients

✍ Scribed by Hisashi Higuchi; Keizo Yoshida; Hitoshi Takahashi; Shingo Naito; Mitsuhiro Kamata; Kenichi Ito; Kazuhiro Sato; Kei Tsukamoto; Tetsuo Shimizu; Mamoru Nakanishi; Yasuo Hishikawa

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 78 KB
• Volume: 18
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.484

✦ Synopsis

Abstract

The relationship between antidepressant effects and plasma levels of milnacipran was studied in 49 cases of major depression without psychotic features during 6 weeks of milnacipran treatment. The daily dose of milnacipran was 50 mg/day for the first week, and up to 100 mg/day thereafter. Depressive symptoms were evaluated by the Montgomery and Åsberg depression rating scale (MADRS) before treatment and at 1, 2, 4 and 6 weeks after the beginning of this study. Thirty‐four patients (69.4%) were responders (defined as a 50% or greater decrease in the baseline MADRS score). Significant differences of MADRS scores were seen from 1 week after the beginning of this study (p = 0.004, unpaired t‐test) between responders and nonresponders. The mean plasma milnacipran level of responders, 82.0 ± 29.4 ng/ml, was similar to that of non‐responders, 78.6 ± 23.1 ng/ml; there was no significant difference between responders and nonresponders. Neither a significant linear nor a curvilinear relationship was obtained between the final MADRS score and the plasma levels of milnacipran. Although there was no significant relationship between the plasma levels of milnacipran and the antidepressant response, milnacipran should be considered an efficacious agent in the treatment of major depressive patients. Copyright © 2003 John Wiley & Sons, Ltd.